Abstract
Background: Chronic pain in cancer survivors negatively impacts quality of life. This study sought to investigate the relationship between high-impact chronic pain (HICP) — defined as chronic pain that limits life or work activities on most days or every day in the past 3 months — and cannabis in cancer survivors.
Methods: An electronic survey was developed in conjunction with the National Cancer Institute Comprehensive Cancer Centers in the United States. This survey was distributed to cancer survivors within a multi-site, single institution setting.
Results: The survey response rate was 23.0% (2304/10,000); 72.7% of these patients (1676/2304) did in fact have a confirmed cancer diagnosis. Among these cancer survivors, 16.5% (unweighted 278/1676) had HICP, and 12.4% (208/1676) reported cannabis use since their cancer diagnosis. The prevalence of past 30-day cannabis use was 12.3% (206/1676). Compared to cancer survivors without pain, those with HICP were more likely to believe in the benefits of cannabis (unweighted 92.1% vs. 74.7%; age-adjusted odds ratio [OR] = 3.1; 95% CI: 1.9-5.1) and less likely to believe in its risks (unweighted 48.2% vs. 58.4%; age-adjusted OR = 0.6; 95% CI: 0.4-0.7).
Conclusions: Cancer survivors with HICP have a higher prevalence of cannabis use compared to those patients without pain. More research is needed to advance pain and symptom management among cancer survivors and to identify clinical scenarios in which benefit is greater than potential harm.
Keywords: cancer, cannabis, chronic pain, surveys
Similar articles
-
Abstracts of Presentations at the Association of Clinical Scientists 143rd Meeting Louisville, KY May 11-14,2022.Ann Clin Lab Sci. 2022 May;52(3):511-525.PMID: 35777803 No abstract available.
-
Suicidal Ideation.2022 May 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.PMID: 33351435 Free Books & Documents.
-
Prevalence and Profile of High-Impact Chronic Pain in the United States.J Pain. 2019 Feb;20(2):146-160. doi: 10.1016/j.jpain.2018.07.006. Epub 2018 Aug 7.PMID: 30096445 Free PMC article.
-
Cannabis-based medicines for chronic neuropathic pain in adults.Cochrane Database Syst Rev. 2018 Mar 7;3(3):CD012182. doi: 10.1002/14651858.CD012182.pub2.PMID: 29513392 Free PMC article. Review.
-
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.Cochrane Database Syst Rev. 2022 May 5;5(5):CD013444. doi: 10.1002/14651858.CD013444.pub2.PMID: 35510826 Review.